1. Fox BJ et al: Papulosquamous diseases: A review. J Am Acad Dermatol 12:597, 1985
2. Johnson BA et al: Treatment of seborrheic dermatitis. Am Fam Physician 61:2703-2714, 2000
3. Szepietowski JC et al: Quality of life in patients suffering from seborrheic dermatitis: Influence of age, gender, and education level. Expert Rev Dermatol 3(1):43-47, 2008
4. Groisser D et al: Association of Pityrosporum orbiculare with seborrheic dermatitis in patients with acquired immunodeficiency syndrome (AIDS). J Am Acad Dermatol 20:770-773, 1989
5. Fischer M et al: Skin function and skin disorders in Parkinson's disease. J Neural Transm 108:205-213, 2001
6. Midgley G: The lipophilic yeasts: State of the art and prospects. Med Mycol 38(1):9-16, 2000
7. Tager A et al: Seborrheic dermatitis in acute cardiac disease. Br J Dermatol 76:367-369, 1964
8. McLaurin CI: Annular facial dermatoses in blacks. Cutis 32:369-370, 1983
9. Barba A et al: Skin lesions in chronic alcoholic pancreatitis. Dermatologica 164:322-326, 1982
10. Johnson M et al: Prevalence of Dermatological Diseases Among Persons 1–74 Years of Age. Washington DC, US Department of Health and Human Services. Publication No. (PHS) 79:1660, 1977
11. Unna PG: Das seborrhoische Ekzem. Monatsschr Prakt Dermatol 6:827-846, 1897
12. Shuster S: The aetiology of dandruff and the mode of action of therapeutic agents. Br J Dermatol 111:235-242, 1984
13. Low RC et al: Discussion on the etiology of seborrhoea and seborrhoeic dermatitis. Br Med J 2:752-757, 1922
14. Jacobs PH: Seborrheic dermatitis: Causes and management. Cutis 41:182-186, 1988
15. DeAngelis YM et al: Three etiologic facets of dandruff and seborrheic dermatitis: Malassezia fungi, sebaceous lipids, and individual sensitivity. J Investig Dermatol 10:295-297, 2007
16. Mayer-da-Silva A et al: Effects of azeleic acid on sebaceous gland, sebum excretion rate and keratinization pattern in human skin. Acta Derm Venereol Suppl 143:20-30, 1989
17. Geissler SE et al: Very low dose
isotretinoin is effective in controlling seborrhea.
J Dtsch Dermatol Ges 1(12):952-958, 2003
18. Parry ME et al: Seborrhoeic dermatitis is not caused by an altered immune response to Malassezia yeast. Br J Dermatol 139(2):254-263, 1998
19. Bergbrant IM et al: Cell-mediated immunity to Malassezia furfur in patients with seborrhoeic dermatitis and pityriasis versicolor. Clin Exp Dermatol 24(5):402-406, 1999
20. Ishibashi Y: Role of Malassezia colonization in cutaneous immune response. (Japanese) Nippon. Ishinkin Gakkai Zasshi. 50(3):147-149, 2009
21. Belew PW et al: Activation of the alternative pathway of complement by Malassezia ovalis (Pityrosporum ovale). Mycopathologia 70(3):187-191, 1980
22. Neuber K et al: Effects of Pityrosporum ovale on proliferation, immunoglobulin synthesis and cytokine production of peripheral blood mononuclear cells from patients with seborrheic dermatitis. Arch Dermatol Res 288:532-536, 1996
23. Hale EK et al: Relation between skin temperature and location of facial lesions in seborrheic dermatitis. Arch Dermatol 136:559, 2000
24. Tegner E: Seborrheic dermatitis of the face induced by PUVA treatment. Acta Derm Venereol Suppl 63:335, 1993
25. Leyden JJ et al: Role of microorganisms in dandruff. Arch Dermatol 112:333, 1976
26. Tajima M et al: Molecular analysis of Malassezia microflora in seborrheic dermatitis patients: Comparison with other diseases and healthy subjects. J Invest Dermatol 128(2):345-351, 2008
27. Shuster S et al: Treatment of seborrheic dermatitis with topical
ketoconazole.
Lancet 2:1271-1272, 1984
28. Cowley NC et al: The permissive effect of sebum in seborrheic dermatitis: An explanation of the rash in neurologic disorders. Br J Dermatol 122:71-76, 1990
29. Binder RL et al: Seborrheic dermatitis in neuroleptic induced parkinsonism. Arch Dermatol 119:473-475, 1983
30. Maietta G et al: Patients with mood depression have a higher prevalence of seborrhoeic dermatitis. Acta Derm Venereol 70:432-434, 1990
31. Higgins EM et al: Skin disease in Gulf war veterans. QJM 95(10):671-676, 2002
32. Van Erp PE et al: Calmodulin levels in psoriasis and other skin disorders. Arch Dermatol Res 279(3):151-153, 1987
33. AbouMourad N et al: Dermopathic changes in hypozincemia. Arch Dermatol 115(8):956-958, 1979
34. Tolleson A et al: Essential fatty acids in infantile seborrheic dermatitis. J Am Acad Dermatol 28:957, 1993
35. Birnbaum RY et al: Seborrhea-like dermatitis with psoriasiform elements caused by a mutation in ZNF750, encoding a putative C2H2 zinc finger protein. Nat Genet 38(7):749-751, 2006
36. Döring HF: Treatment of sebopsoriasis. A clinical trial, and etiological approach. Dermatologica 169(Suppl. 1):125-133, 1984
37. Al-Dhalimi MA: Neonatal and infantile erythroderma: A clinical and follow-up study of 42 cases. J Dermatol 34(5):302-307, 2007
38. Elish D et al: Infantile seborrheic dermatitis. Cutis 77(5):297-300, 2006
39. Leiner C: Uber Erythrodermia desquamtiva, eine eigenartige universelle Dermatose der Brustkinder. Arch Dermatol Syphilol 89:65, 1908
40. Jacobs JC et al: Fatal familial Leiner's disease: A deficiency of the opsonic activity of serum complement. Pediatrics 49(2):225-232, 1972
41. Alibert JL: La porrigine amiantacea, Paris, France. Monographie des Dermatoses 1:293-295, 1832
42. Abdel-Hamid IA et al: Pityriasis amiantacea: A clinical and etiopathologic study of 85 patients. Int J Dermatol 42(4):260-264, 2003
43. Hussain W et al: Pityriasis amiantacea as the sole manifestation of Darier's disease. Clin Exp Dermatol 34(4):554-556, 2009
44. Faergemann J: Severe seborrheic dermatitis. J Int Postgrad Med 2:18-20, 1990
45. Soeprono FF et al: Seborrheic-like dermatitis of acquired immunodeficiency syndrome: A clinicopathologic study. J Am Acad Dermatol 14:242, 1986
46. Nnoruka EN et al: Correlation of mucocutaneous manifestations of HIV/AIDS infection with CD4 counts and disease progression. Int J Dermatol 46(Suppl. 2):14-18, 2007
47. Weedon D: Skin Pathology: Seborrheic Dermatitis, 2nd edition. Philadelphia, USA, Churchill Livingston, Elsevier Science Limited, 2002, pp. 107-109.
48. Arora V et al: Management of infantile seborrheic dermatitis. Am Fam Physician 75(6):807, 2007
49. Janniger CK: Infantile seborrheic dermatitis: An approach to cradle cap. Cutis 51(4):233-235, 1993
50. Wannanukul S et al: Malassezia furfur in infantile seborrheic dermatitis. Asian Pac J Allergy Immunol 23(2-3):101-105, 2005
51. Wannanukul S et al: Comparative study of 2%
ketoconazole cream and 1%
hydrocortisone cream in the treatment of infantile seborrheic dermatitis.
J Med Assoc Thai 87(Suppl. 2):S68-S71, 2004
52. Arndt KA et al: Manual of Dermatologic Therapeutics with Essentials of Diagnosis, 5th edition. Boston, Little Brown & Co., 1995, p. 166
53. Shin H et al: Clinical efficacies of topical agents for the treatment of seborrheic dermatitis of the scalp: A comparative study. J Dermatol 36(3):131-137, 2009
54. Peter RU et al: Successful treatment and prophylaxis of scalp seborrhoeic dermatitis and dandruff with 2%
ketoconazole shampoo.
Br J Dermatol 132:441-445, 1995
55. Schwartz JR et al: Does tachyphylaxis occur in long-term management of scalp seborrheic dermatitis with pyrithione zinc-based treatments? Int J Dermatol 48(1):79-85, 2009
56. Nowicki R: Modern management of dandruff. Pol Merkur Lekarski 20(115):121-124, 2006
57. Young AW Jr: Seborrhea in the geriatric patient: Incidence, implication, management. Geriatrics 24(3):144-150, 1969
58. Bikowski J: Facial seborrheic dermatitis: A report on current status and therapeutic horizons. J Drugs Dermatol 8(2):125-133, 2009
59. Firooz A et al:
Pimecrolimus cream, 1%, vs.
hydrocortisone acetate cream, 1%, in the treatment of facial seborrheic dermatitis.
Arch Dermatol 142(8):1066-1067, 2006
60. Tatlican S et al: Experience with repetitive use of
pimecrolimus: Exploring the effective and safe use in the treatment of relapsing seborrheic dermatitis.
J Dermatolog Treat 1:1-3, 2009
61. Cook BA et al: Role of topical calcineurin inhibitors in the treatment of seborrheic dermatitis: A review of pathophysiology, safety, and efficacy. Am J Clin Dermatol 10(2):103-118, 2009
62. Koc E et al: Topical
pimecrolimus 1% cream and topical
ketoconazole 2% cream in the treatment of seborrheic dermatitis.
J Dermatolog Treat 20(1):4-9, 2009
63. Faergemann J et al: A new
ketoconazole topical gel formulation in seborrhoeic dermatitis: An updated review of the mechanism.
Expert Opin Pharmacother 8(9):1365-1371, 2007
64. Ratnavel RC et al: Clinical efficacies of shampoos with
ciclopirox olamine (1.5%),
ketoconazole (2.0%) in treatment of seborrhoeic dermatitis.
J Dermatolog Treat 18(2):88-96, 2007
65. Paghdal KV et al: Topical tar: Back to the future. J Am Acad Dermatol 61(2):294-302, 2009
66. Jackson WB: Blepharitis: Current strategies for diagnosis and management. Can J Ophthalmol 43(2):170-179, 2008
67. Gupta AK et al: Etiology and management of seborrheic dermatitis. Dermatology 208(2):89-93, 2004
68. Faergemann J: Management of seborrheic dermatitis and pityriasis versicolor. Am J Clin Dermatol 1(2):75-80, 2000
69. Gupta AK et al: Role of antifungal agents in the treatment of seborrheic dermatitis. Am J Clin Dermatol 5(6):417-422, 2004
70. Vena GA et al: Oral
terbinafine in the treatment of multi-site seborrheic dermatitis.
Int J Immunopathol Pharmacol 18(4):745-753, 2005
71. Sparsa A et al:
Lithium.
Ann Dermatol Venereol 131(3):255-261, 2004
73. Orfanos CE et al: Oral retinoids in treatment of seborrhea, acne. Dermatology 196:140-147, 1998
74. Wikler JR et al: The effect of UV-light on pityrosporum yeasts: Ultrastructural changes and inhibition of growth. Acta Derm Venereol 70:69-71, 1990